Bone marrow stromal cells are essential for B-lymphocyte development. However, how stromal cells regulate B lymphopolesis is not clear. In this paper, we report the molecular cloning of a stromal cell line-derived glycosylphosphatidylinositol-anchored molecule, BST-1, that facilitates pre-B-cell growth. The deduced amino acid sequence of BST-1 exhibited 33% identit with CD38. BST-1 was expressed in a wide range of tissues and in umbiLical vein endothelial cells,
The growth and development ofB-lineage cells are regulated by close associations between hematopoietic cells and the bone marrow (BM) microenvironment (1) (2) (3) (4) . BM-derived stromal cells not only produce soluble factors but also express surface molecules that are key molecules acting on B-lineage cells. For example, interleukin 7 (IL-7) is a stromal cell-derived factorthat stimulates B-lineage cell growth (5) . Stem-cell factor (SCF) is also involved in B lymphopoiesis, since it shows B-cell growthstimulatory activity in synergy with IL-7 (6) (7) (8) . In addition to these factors, other adhesion molecules on stromal cells are crucial for B lymphopoiesis. CD44 and VCAM-1 are involved in in vitro interaction between stromal cells and lymphocytes (9, 10) . Surrogate inmunoglobulin light-chain complexes on B-cell progenitors that can transduce activating signals are essential for normal B lymphopoiesis (11) , suggesting the presence of ligand for the surrogate light-chain complexes in the BM microenvironments. Further, it has been suspected that yet unknown stromal cell molecules may be involved in B-lineage cell growth and development (12, 13) . We have found that BM stromal cell lines derived from rheumatoid arthritis (RA) patients may provide such unidentified cell surface molecules (14) .
To identify these unknown molecules, we prepared monoclonal antibodies (mAbs), RF3 14 and data not shown), we first prepared murine mAbs against these cell lines to identify the stromal cell surface molecules involved in pre-B-cell growth. We selected two mAbs, RF3 (IgG2a) and SG2 (IgG2a), that were reactive with RASV5-5 and SynSV6-14, but not with a healthy donor-derived nonsupportive cell line, NFSV1-1 (data not shown). RF3 inhibited the reactivity of SG2 for RASV5-5 and vice versa, suggesting that these two antibodies recognize closely located epitopes on the same molecule (data not shown). The molecule recognized by RF3 and SG2 was termed BST-1.
Molecular Cloning ofBST-i. To characterize the molecular nature of BST-1, we cloned the cDNA, p63-BOS, by expression cloning. This clone conferred on transfected 293T cells reactivity with both RF3 and SG2 ( Fig. 1 A and B) , confirming that the two mAbs recognize the same molecule. Further, the reactivity with RF3 was inhibited by culture supernatants of 293T cells transfected with pA63-BOS (Fig. 1C) , which encodes a soluble form of BST-1, suggesting that the insert cDNA ofp63-BOS encodes BST-1 itself, but not the molecule (Fig. 2) . In this frame, the initiator ATG is followed by 317 codons before the termination triplet TAA. Since hydrophobic amino acids are abundant in residues 1-28, this region appears to be a typical signal peptide, suggesting that the mature protein probably consists of 290 amino acids. Amino Add Homology of BST-1 with CD38 and ADPRibosyl Cyclase. The nucleotide sequence ofthe insert cDNA was compared with other DNAs in the GenBank (release 76) and EMBL (release 34) data bases by GENEWORKS 2.2.1 (IntelliGenetics); no significant similarity with any known DNA sequences was found. However, comparison of the deduced amino acid sequence of BST-1 with the Swiss-Prot (release 25) protein data base revealed that BST-1 showed 33% amino acid identity with human lymphocyte antigen CD38 (Fig. 3) (21, 22) , which exhibited a 291% identity with Aplysia ADP-ribosyl cyclase (23) . BST-1 itself showed less but significant (26%) identity with the cyclase. The positions of nine cysteine residues in the extracellular region of BST-1 were completely conserved among CD38 and the cyclase, suggesting that these molecules may be distantly related. examined by Northern blot analysis (Fig. 4) Cells were incubated without (control) or with RF3 and were washed before addition of fluorescein-labeled goat anti-mouse 1g. Efect of BST-1 on DW34 Cell Growth. To examine whether BST-1 was involved in pre-B-cell growth, we transfected p63-BOS into a murine fibroblast cell line, BALB 3T3, and obtained several stable transfectants expressing human BST-1. These transfectants were cocultured with a stromal cell-dependent mouse pre-B-cell line, DW34 (20) Enhanced Expressn of BST-1 on RA BM-Derived Strnal Cell Lines. Surface expression ofBST-1 on panels ofRA, MM, and healthy donor-derived BM stromal cell lines was investigated by flow cytofluorometry (Fig. 6) . The Although BST-1 is a GPI-linked membrane protein, whereas CD38 is a type II integral membrane protein, they showed a similar overall amino acid structure, suggesting that BST-1 may have a function similar to that of CD38. Anti-CD38 induces an increase of intracellular Ca2+ and an immunoglobulin-independent activation and proliferation of B cells (26) . This activation is suggested to be mediated by the ADP-ribosyl cyclase activity of CD38 that catalyzes the synthesis of cyclic ADP-ribose from nicotinamide adenine dinucleotide (27) . Cyclic ADP-ribose is a potent mediator to induce Ca2+ release independently of the inositol 1,4,5-trisphosphate receptor (28, 29) . However, it is unknown how CD38 plays a role in B-cell activation as a cell surface enzyme.
Human CD38 is expressed on immature lymphocytes and has been suggested to be involved in lymphocyte development (21, 22 RA is a systemic autoimmune disease of unknown etiology and primarily affects joint synovial tissues. We previously showed that RA-derived BM stromal cell lines had an enhanced ability to support pre-B cell growth (14) . Further, the expression of BST-1 was enhanced in RA-derived BM stromal cell lines compared with healthy donor-derived ones, suggesting the presence of abnormalities in the BM microenvironment in RA patients. This hypothesis may be supported by the fact that BM transplantation resulted in a complete remission ofRA or psoriatic arthritis in certain cases (30, 31) . Although it remains to be clarified how BST-1 functions in vivo, we assume that polyclonal B-cell abnormalities in RA may be, at least in part, attributed to BST-1 overexpression on the stromal cell population. The molecular mechanism(s) that induces such abnormal expression of multiple genes, including those encoding BST-1 and IL-6, may lead to better understanding of the etiology of RA (32, 33) .
